Clinical trialNCT01182350TerminatedPhase 2Interventional

Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)

SponsorKaren D. Wright MDEnrollment53Diffuse Intrinsic Pontine Glioma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Diagnosis of diffuse intrinsic pontine glioma (DIPG) for decades has relied on imaging studies and clinical findings. Histologic confirmation has been absent with surgical biopsy of brainstem tumors not believed to have acceptable safety. The prognosis of DIPG has remained quite poor and novel therapeutic strategies are needed. This DIPG Biology and Treatment Study (DIPG-BATS) study incorporates a surgical biopsy at presentation using strict preoperative neurosurgical planning and stratifies participants to receive FDA-approved agents chosen on the basis of specific biologic targets. This is the first prospective national clinical trial to examine the feasibility and safety of incorporating surgical biopsy into potential treatment strategies for children with DIPG.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Karen D. Wright, MD
Dana-Farber Cancer Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

23 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Phoenix Children'S Hospital
Phoenix, Arizona, United States
Children'S Hospital Los Angeles
Los Angeles, California, United States
Stanford University/lucile Packard Children'S Hospital
Palo Alto, California, United States
University of California, San Francisco
San Francisco, California, United States
Children'S Hospital Colorado
Aurora, Colorado, United States
Nemours Children'S Clinic
Jacksonville, Florida, United States
Miami Children'S Hospital
Miami, Florida, United States
Children'S Healthcare of Atlanta
Atlanta, Georgia, United States
Ann & Robert H Lurie Children'S Hospital of Chicago
Chicago, Illinois, United States
University of Louisville
Louisville, Kentucky, United States
Johns Hopkins
Baltimore, Maryland, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Children'S Hospital of Michigan
Detroit, Michigan, United States
Children'S Hospitals and Clinics of Minnesota
Minneapolis, Minnesota, United States
Washington University Medical Center
St Louis, Missouri, United States
New York University
New York, New York, United States
Duke University
Durham, North Carolina, United States
Doernbecher Children'S Hospital
Portland, Oregon, United States
Penn State Hershey Medical Center
Hershey, Pennsylvania, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Ut Southwestern Medical Center
Dallas, Texas, United States
Cook Children'S Medical Center
Fort Worth, Texas, United States
Seattle Children'S Hospital
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bevacizumab →Erlotinib →Temozolomide →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Sept 2011
Primary completion: 30 Jun 2016
Completion: 30 Jun 2016
Last update posted: 4 Sept 2019
Registered enrollment: 53
Registry id: NCT01182350

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.